ALX Oncology Evorpacept Phase 1b/2 trial shows 100% cORR in high CD47 mBC
ALX Oncology announced positive data from exploratory analyses of its Phase 1b/2 clinical trial for evorpacept in combination with zanidatamab for heavily pre-treated HER2-positive metastatic breast cancer. The findings, presented at ESMO Breast Cancer 2026, showed a 100% confirmed objective response rate and significantly longer median progression-free survival (22.1 months) in patients with high CD47 expression. These results further validate a biomarker-driven development strategy for evorpacept. The company also scheduled a webcast for May 8, 2026, to discuss Q1 2026 financial results and the trial data.
Key Highlights
- Evorpacept Phase 1b/2 trial showed 100% confirmed objective response rate (cORR) in HER2-positive mBC patients with high CD47 expression (n=5/5).
- Patients with high CD47 expression had a median progression-free survival (mPFS) of 22.1 months, compared to 3.4 months for low CD47 expression.
- Median duration of response (mDOR) was 20.2 months in patients with high CD47 expression.
- Overall cORR among all 24 patients was 33%, with an mPFS of 3.6 months.
- Patients with centrally confirmed HER2-positive disease (n=10) had a cORR of 60% and mPFS of 8.3 months.
- ALX Oncology will host a webcast on May 8, 2026, to report first quarter 2026 financial results and discuss trial data.
Price Impact
More from ALXO
More in Clinical Trial
Opus Genetics Presents Positive Clinical Data for OPGx-BEST1 and OPGx-LCA5 Gene Therapies
Krystal Biotech: KB113 Shows Over 80% Lesion Regression in Gorlin Syndrome Study
Eupraxia Pharmaceuticals to Present EoE Trial Data at ACG and UEG Conferences